A Phase 3 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 5th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 555 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 3, and was the 12th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.
Select Inclusion Criteria:
Select Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pirfenidone
Drug: Placebo
Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
Placebo equivalent given as 3 divided doses 3 times per day.
Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52
Time frame: 52 weeks
| Milestone | Active Arm | Placebo Arm |
|---|---|---|
| Started | 278 | 277 |
| Completed | 243 | 241 |
| Not completed | 35 | 36 |
| Withdrew: Adverse event | 6 | 7 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Death | 12 | 19 |
| Withdrew: Lung transplantation | 6 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Sponsors decision | 0 | 1 |
| Withdrew: Withdrew consent | 4 | 3 |
| percentage of patients | Active Arm | Placebo Arm |
|---|---|---|
| Decline or >=10% or Death | 16.5 | 31.8 |
| No Decline (Change >0%) | 22.7 | 9.7 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Arm | — | 55/278 (19.8%) | 271/278 (97.5%) |
| Placebo Arm | — | 69/277 (24.9%) | 253/277 (91.3%) |
| Event | Active Arm | Placebo Arm |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 7/278 | 27/277 |
| pneumoniaInfections and infestations | 11/278 | 14/277 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/278 | 4/277 |
| Angina PectorisCardiac disorders | 3/278 | 0/277 |
| NauseaGastrointestinal disorders | 3/278 | 0/277 |
| Atrial FibrillationCardiac disorders | 1/278 | 2/277 |
| BronchitisInfections and infestations | 1/278 | 2/277 |
| Gastroenteritis viralInfections and infestations | 0/278 | 2/277 |
| Septic shockInfections and infestations | 1/278 | 2/277 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/278 | 2/277 |
| Event | Active Arm | Placebo Arm |
|---|---|---|
| NauseaGastrointestinal disorders | 100/278 | 37/277 |
| CoughRespiratory, thoracic and mediastinal disorders | 70/278 | 82/277 |
| RashSkin and subcutaneous tissue disorders | 78/278 | 24/277 |
| HeadacheNervous system disorders | 72/278 | 64/277 |
| DiarrhoeaGastrointestinal disorders | 62/278 | 60/277 |
| Upper respiratory tract infectionInfections and infestations | 61/278 | 56/277 |
| FatigueGeneral disorders | 58/278 | 48/277 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 41/278 | 49/277 |
| DyspepsiaGastrointestinal disorders | 49/278 | 17/277 |
| DizzinessNervous system disorders | 49/278 | 36/277 |
| Age, Categorical(Participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 73 | 88 | 161 |
| >=65 years | 205 | 189 | 394 |
| Sex: Female, Male(Participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| Female | 56 | 64 | 120 |
| Male | 222 | 213 | 435 |
| Region of Enrollment(participants) | Active Arm | Placebo Arm | Total |
|---|---|---|---|
| United States | 187 | 184 | 371 |
| Australia | 33 | 31 | 64 |
| Brazil | 15 | 16 | 31 |
| Croatia | 1 | 1 | 2 |
| Israel | 11 | 9 | 20 |
| Mexico | 12 | 5 | 17 |
| New Zealand | 1 | 3 | 4 |
| Peru | 18 | 26 | 44 |
| Singapore | 0 | 2 | 2 |
The record gives a start of Jun 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
Idiopathic Pulmonary Fibrosis →